FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557103694> ?p ?o ?g. }

• W2557103694 endingPage "3602" @default.
• W2557103694 startingPage "3602" @default.
• W2557103694 abstract "Abstract Acute Myeloid Leukemia (AML) and Myelodysplastic syndrome (MDS) arise from accumulation of multiple stepwise genetic and epigenetic changes in hematopoietic stem cells (HSC) and/or committed progenitors. A series of transforming events can initially give rise to pre-leukemia stem cells (pre-LSC) as well as fully transformed leukemia stem cells (LSC), both of which need to be targeted in strategies aimed at curing these diseases. We conducted parallel transcriptional and epigenetic analysis of highly fractionated stem and progenitor populations in individual patients of MDS and identified STAT3 upregulation in MDS HSCs. qRTPCR in an independent set of sorted MDS/AML HSCs (Lineage-negative, CD34+, CD38-) confirmed the significant increase in STAT3 expression in 60% of cases when compared to healthy controls. We further analyzed gene expression profiles of CD34+ cells from 183 MDS patients and found significant increased expression of STAT3 in MDS when compared to healthy controls (FDR<0.1) and importantly, found that increased STAT3 expression was predictive of significantly adverse prognosis (log rank P value < 0.01, median survival of 2.6 years compared to 5.8 years for group with lower STAT3) in patients. This further points to a critical role of STAT3 signaling in AML/MDS pathogenesis and progression. Next, we studied the functional role of STAT3 by using Pyrimethamine as a clinically relevant inhibitor. Pyrimethamine is an FDA approved antifolate compound that was found to be a specific inhibitor of STAT3 activity in an initial screen of 1120 compounds. 3D modeling studies reveal that Pyrimethamine can occupy the SH2 domain of STAT3 protein with high avidity. It shows half-maximal activity (EC50) for STAT3 inhibition at approximately 1.5 μM, well within the plasma concentrations found with clinical use. We assessed the effect of Pyrimethamine on cellular proliferation of multiple leukemic cell lines (KG-1, KT-1 and CMK), and observed that these were significantly inhibited at 120 hours of exposure in a dose dependent fashion (t test, p value <0.004, Mean + SD of 3 experiments). Pyrimethamine was also able to induce significant apoptosis in AML cell lines at 72 hours at a 10 μM concentration. (P Value <0.05) In summary, we have found significant demethylation and increased expression of STAT3 in sorted HSCs from AML and MDS patients. High STAT3 expression is a marker of adverse prognosis in a large cohort of MDS patients. In vitro studies show that Pyrimethamine can inhibit STAT3 activation and is able to inhibit proliferation by inducing apoptosis in leukemic cells. A phase II study evaluating Pyrimethamine for the treatment of intermediate/high-risk MDS patients that have relapsed or are refractory to azanucleoside therapy has been initiated. Disclosures Brown: Sanofi, Onyx, Vertex, Novartis, Boehringer, GSK, Roche/Genentech, Emergent, Morphosys, Celgene, Janssen, Pharmacyclics, Gilead: Consultancy." @default.
• W2557103694 created "2016-11-30" @default.
• W2557103694 creator A5012812748 @default.
• W2557103694 creator A5016570475 @default.
• W2557103694 creator A5017739829 @default.
• W2557103694 creator A5033524932 @default.
• W2557103694 creator A5039886481 @default.
• W2557103694 creator A5040239548 @default.
• W2557103694 creator A5042514392 @default.
• W2557103694 creator A5042546543 @default.
• W2557103694 creator A5045304815 @default.
• W2557103694 creator A5046121522 @default.
• W2557103694 creator A5047880272 @default.
• W2557103694 creator A5049994646 @default.
• W2557103694 creator A5053723355 @default.
• W2557103694 creator A5056232980 @default.
• W2557103694 creator A5071909219 @default.
• W2557103694 creator A5077804779 @default.
• W2557103694 date "2014-12-06" @default.
• W2557103694 modified "2023-10-13" @default.
• W2557103694 title "Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine" @default.
• W2557103694 doi "https://doi.org/10.1182/blood.v124.21.3602.3602" @default.
• W2557103694 hasPublicationYear "2014" @default.
• W2557103694 type Work @default.
• W2557103694 sameAs 2557103694 @default.
• W2557103694 citedByCount "6" @default.
• W2557103694 countsByYear W25571036942017 @default.
• W2557103694 countsByYear W25571036942018 @default.
• W2557103694 countsByYear W25571036942023 @default.
• W2557103694 crossrefType "journal-article" @default.
• W2557103694 hasAuthorship W2557103694A5012812748 @default.
• W2557103694 hasAuthorship W2557103694A5016570475 @default.
• W2557103694 hasAuthorship W2557103694A5017739829 @default.
• W2557103694 hasAuthorship W2557103694A5033524932 @default.
• W2557103694 hasAuthorship W2557103694A5039886481 @default.
• W2557103694 hasAuthorship W2557103694A5040239548 @default.
• W2557103694 hasAuthorship W2557103694A5042514392 @default.
• W2557103694 hasAuthorship W2557103694A5042546543 @default.
• W2557103694 hasAuthorship W2557103694A5045304815 @default.
• W2557103694 hasAuthorship W2557103694A5046121522 @default.
• W2557103694 hasAuthorship W2557103694A5047880272 @default.
• W2557103694 hasAuthorship W2557103694A5049994646 @default.
• W2557103694 hasAuthorship W2557103694A5053723355 @default.
• W2557103694 hasAuthorship W2557103694A5056232980 @default.
• W2557103694 hasAuthorship W2557103694A5071909219 @default.
• W2557103694 hasAuthorship W2557103694A5077804779 @default.
• W2557103694 hasConcept C10205521 @default.
• W2557103694 hasConcept C109159458 @default.
• W2557103694 hasConcept C159912055 @default.
• W2557103694 hasConcept C201750760 @default.
• W2557103694 hasConcept C203014093 @default.
• W2557103694 hasConcept C2778461978 @default.
• W2557103694 hasConcept C2778729363 @default.
• W2557103694 hasConcept C2779282312 @default.
• W2557103694 hasConcept C28328180 @default.
• W2557103694 hasConcept C502942594 @default.
• W2557103694 hasConcept C54355233 @default.
• W2557103694 hasConcept C71924100 @default.
• W2557103694 hasConcept C86803240 @default.
• W2557103694 hasConceptScore W2557103694C10205521 @default.
• W2557103694 hasConceptScore W2557103694C109159458 @default.
• W2557103694 hasConceptScore W2557103694C159912055 @default.
• W2557103694 hasConceptScore W2557103694C201750760 @default.
• W2557103694 hasConceptScore W2557103694C203014093 @default.
• W2557103694 hasConceptScore W2557103694C2778461978 @default.
• W2557103694 hasConceptScore W2557103694C2778729363 @default.
• W2557103694 hasConceptScore W2557103694C2779282312 @default.
• W2557103694 hasConceptScore W2557103694C28328180 @default.
• W2557103694 hasConceptScore W2557103694C502942594 @default.
• W2557103694 hasConceptScore W2557103694C54355233 @default.
• W2557103694 hasConceptScore W2557103694C71924100 @default.
• W2557103694 hasConceptScore W2557103694C86803240 @default.
• W2557103694 hasIssue "21" @default.
• W2557103694 hasLocation W25571036941 @default.
• W2557103694 hasOpenAccess W2557103694 @default.
• W2557103694 hasPrimaryLocation W25571036941 @default.
• W2557103694 hasRelatedWork W140795156 @default.
• W2557103694 hasRelatedWork W1694703176 @default.
• W2557103694 hasRelatedWork W1708950638 @default.
• W2557103694 hasRelatedWork W1978656142 @default.
• W2557103694 hasRelatedWork W2047943279 @default.
• W2557103694 hasRelatedWork W2073101215 @default.
• W2557103694 hasRelatedWork W2103129051 @default.
• W2557103694 hasRelatedWork W2362416522 @default.
• W2557103694 hasRelatedWork W2565155465 @default.
• W2557103694 hasRelatedWork W2740899796 @default.
• W2557103694 hasVolume "124" @default.
• W2557103694 isParatext "false" @default.
• W2557103694 isRetracted "false" @default.
• W2557103694 magId "2557103694" @default.
• W2557103694 workType "article" @default.